Silencing FOXP2 reverses vemurafenib resistance in BRAF^V600E mutant papillary thyroid cancer and melanoma cells.

ABSTRACT:

Background

Vemurafenib (VEM) is a commonly used inhibitor of papillary thyroid cancer (PTC) and melanoma with the BRAF^V600E mutation; however, acquired resistance is unavoidable. The present study aimed to identify a potential target to reverse resistance.

Materials and methods

A VEM-resistant PTC cell line (B-CPAP/VR) was established by gradually increasing the drug concentration, and a VEM-resistant BRAF^V600E melanoma cell line (A375/VR) was also established. RNA sequencing and bioinformatics analyses were conducted to identify dysregulated genes and construct a transcription factor (TF) network. The role of a potential TF, forkhead box P2 (FOXP2), verified by qRT-PCR, was selected for further confirmation.

Results

The two resistant cell lines

SUBMITTER: Jiang S 

PROVIDER: S-EPMC9813165 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature